You are here

Article Text

Article menu

Download PDFPDF

Therapeutics/Prevention
Randomised controlled trial
Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis
Free
  1. Gareth Pryce,
  2. David Baker
  1. Department of Neuroscience, Queen Mary University of London, London, UK
  1. Correspondence to : Dr Gareth Pryce, Centre for Neuroscience, Blizard Institute, Barts and The London School of Medicine and Dentistry, QMUL, 4 Newark Street, London E1 2AT, UK; g.pryce{at}qmul.ac.uk

https://doi.org/10.1136/ebmed-2015-110198

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Ball S, Vickery J, Hobart J, et al. The Cannabinoid Use in Progressive Inflammatory brain disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Health Technol Asess 2015;19:1–187.OpenUrl

    Context

    Despite the increasing number of effective disease modifying therapies for multiple sclerosis (MS), there are no effective therapies for the progressive, neurodegenerative phase of the disease. There is now abundant experimental evidence that cannabinoids and the endocannabinoid system are protective factors in animal models of MS and also other neurodegenerative conditions. This randomised controlled trial (RCT) aimed to investigate the potential neuroprotective properties of the prototypical cannabinoid Δ 9-tetrahydrocannabinol (THC) as measured by the slowing of the progressive phase …

    View Full Text